Apimeds Pharmaceuticals US, Inc
APUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $18 | $25 | $25 |
| - Cash | $7 | $9 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | – | $10 | $26 | $26 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.14 | -0.26 | -0.035 | -0.025 |
| % Growth | 46.2% | -647.1% | -41.5% | – |
| Operating Cash Flow | -$2 | -$3 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$2 | -$3 | -$0 | -$0 |